跳至主要内容

MedPath Trial Home

机构资讯 AI 研究

数据来源：ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

搜索试验。追踪管线。洞察审批。由 AI 驱动的临床研究情报平台。

产品

临床试验
药物情报
全球审批
深度研究
价格方案

资源

常见问题
搜索

公司

资讯
关于我们
联系我们

法律

隐私政策
服务条款

免责声明： 本网站提供信息检索和数据分析服务。内容不构成医疗建议。适应性评估仅供参考，不能替代合格医疗专业人员的咨询。数据来源于公共注册库和监管机构；MedPath 不保证数据的完整性或准确性。请以原始资料为准。

© 2026 MedPath Trial 版权所有

服务条款隐私政策

我们重视您的隐私

我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。

PFIZER, INC.

首页临床试验发起方与机构PFIZER, INC.

PFIZER, INC.

10501 80TH Ave, Pleasant Prairie, Wisconsin, 美国

Share to Twitter Share to Facebook Share to LinkedIn Share to Reddit

相关临床试验

32

26 进行中

药物批准

2

批准总数

监管机构

1

监管机构数

成立时间

N/A

概览

试验阶段分布

阶段

试验数

占比

1 期

17

53.1%

试验状态分布

进行中（未招募）

26

81.3%

已完成

5

15.6%

招募中

1

3.1%

相关临床试验

该机构主办的试验（32）

A Phase 1, Open-Label, Non-Randomized, 2-Period, Fixed Sequence Study to Investigate the Absorption, Distribution, Metabolism and Excretion of [14c-Pf-06700841] and to Assess the Absolute Bioavailability and Fraction Absorbed of Pf-06700841 in Healthy Male Subjects using a 14C-Microtracer Approach

A phase 1, open-label, randomized, 2-period, 2-sequence, crossover study to evaluate the bioequivalence of Bosutinib pediatric capsule and the commercial tablet formulations in healthy participants under fed conditio

66 名受试者

A PHASE 1, OPEN-LABEL, FIXED SEQUENCE, 2-PERIOD STUDY IN HEALTHY ADULT MALE PARTICIPANTS TO ASSESS THE MASS BALANCE, ABSOLUTE BIOAVAILABILITY, FRACTION ABSORBED, AND PHARMACOKINETICS OF [14C]PF-06882961

A phase 1, open-label, non-randomized, 2-period, fixed sequence study to investigate the absorption, distribution, metabolism and excretion of 14C-PF-06651600 and to assess the absolute bioavailability and fraction absorbed of PF-06651600 in healthy male participants using a 14C-microtracer approach

A phase 1, open-label, 2-period, fixed sequence, study to investigate the absorption, metabolism and excretion of 14C-PF-06650833 and to assess the absolute bioavailability and fraction absorbed of PF-06650833 in healthy male subjects using a 14C-microdose approach.

A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese infants and young childre

进行中（未招募）

A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age

进行中（未招募）

A Study to Evaluate the Efficacy and Tolerability of Rimegepant for Acute Migraine Attacks in Adults for whom Triptans are unsuitable

Dec 2022600 名受试者

药物批准

按机构分类的批准

PHILIPPINES

Philippines FDA

2

药物批准

近期批准

Comirnaty Original/Omicron B.A.4-5

15 September 2022

资讯

Arkansas Attorney General Sues 22 Drug Companies Over Alleged 340B Discount Restrictions

- Arkansas AG Tim Griffin filed a lawsuit against 22 entities, including 13 major drug manufacturers, alleging illegal limits on 340B prescription drug discounts. - The lawsuit accuses companies including Pfizer, Johnson & Johnson, Eli Lilly, and Novo Nordisk of violating Arkansas Act 1103, the 340B Drug Pricing Nondiscrimination Act. - Griffin cited over 300,000 instances of allegedly violative conduct, with the state seeking civil penalties under the Arkansas Deceptive Trade Practices Act. - The legal action follows a 2024 U.S. Supreme Court loss for PhRMA, which had challenged the Arkansas law as unconstitutional on behalf of several manufacturers.

本页目录

概览
相关临床试验32
药物批准2
资讯1

返回机构列表